<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?origin publisher?><?properties no_embargo?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res Treat</journal-id><journal-title>Breast Cancer Research and Treatment</journal-title><issn pub-type="ppub">0167-6806</issn><issn pub-type="epub">1573-7217</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>Boston</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17453340</article-id><article-id pub-id-type="publisher-id">9562</article-id><article-id pub-id-type="doi">10.1007/s10549-007-9562-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Epidemiology</subject></subj-group></article-categories><title-group><article-title>Estrogen receptor &#x003b1; polymorphisms and postmenopausal breast cancer risk</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Gonz&#x000e1;lez-Zuloeta Ladd</surname><given-names>A. M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>V&#x000e1;squez</surname><given-names>A. Arias</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rivadeneira</surname><given-names>F.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Siemes</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hofman</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stricker</surname><given-names>B. H. Ch.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pols</surname><given-names>H. A. P.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Uitterlinden</surname><given-names>A. G.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>van Duijn</surname><given-names>C. M.</given-names></name><address><phone>+31-104087394</phone><fax>+31-104089406</fax><email>c.vanduijn@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Epidemiology &#x00026; Biostatistics, Erasmus MC, P.O. Box 2040, Rotterdam, 3000 CA The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>4</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2008</year></pub-date><volume>107</volume><issue>3</issue><fpage>415</fpage><lpage>419</lpage><history><date date-type="received"><day>6</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>7</day><month>3</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; Springer Science+Business Media, LLC 2007</copyright-statement></permissions><abstract><sec><title>Background</title><p>The estrogen receptor alpha (ESR1) is a mediator of estrogen response in the breast. The most studied variants in this gene are the <italic>PvuII</italic> and <italic>XbaI</italic> polymorphisms, which have been associated to lower sensitivity to estrogen. We evaluated whether these polymorphisms were associated with breast cancer risk by means of an association study in a population of Caucasian postmenopausal women from the Rotterdam study and a meta-analysis of published data.</p></sec><sec><title>Methods</title><p>The <italic>PvuII</italic> and <italic>XbaI</italic> polymorphisms were genotyped in 3,893 women participants of the Rotterdam Study. Baseline information was obtained through a questionnaire. We conducted logistic regression analyses to assess the risk of breast cancer by each of the ESR1 genotypes. Meta-analyses of all publications on these relations were done by retrieving literature from Pubmed and by further checking the reference lists of the articles obtained.</p></sec><sec><title>Results</title><p>There were 38 women with previously diagnosed breast cancer. During follow-up, 152 were additionally diagnosed. The logistic regression analyses showed no difference in risk for postmenopausal breast cancer in carriers of the <italic>PvuII</italic> or <italic>XbaI</italic> genotypes neither in overall, incident or prevalent cases. No further evidence of a role of these variants was found in the meta-analysis.</p></sec><sec><title>Conclusions</title><p>Our results suggest that the ESR1 polymorphisms do not play a role in breast cancer risk in Caucasian postmenopausal women.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Estrogen receptor</kwd><kwd>Polymorphism</kwd><kwd>Breast cancer</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC. 2008</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Family history is one of the strongest risk factors for breast cancer [<xref ref-type="bibr" rid="CR1">1</xref>]. It has been shown that the heritability of this disease is &#x0223c;30% [<xref ref-type="bibr" rid="CR2">2</xref>]. The most important determinants of risk for breast cancer are related to endogenous hormone levels and major reproductive events [<xref ref-type="bibr" rid="CR3">3</xref>], thus, suggesting that genes in the estrogen pathway may influence breast cancer risk.</p><p>The estrogen receptor alpha (ESR1) is one of the most important mediators of hormonal response in estrogen-sensitive tissues such as the breast [<xref ref-type="bibr" rid="CR4">4</xref>] and plays a crucial role in breast growth and differentiation as well as in the development of cancer [<xref ref-type="bibr" rid="CR5">5</xref>]. The human ESR1 gene is localized on chromosome 6q24-q27 [<xref ref-type="bibr" rid="CR6">6</xref>], it extends more than 140&#x000a0;kb and includes eight exons [<xref ref-type="bibr" rid="CR7">7</xref>]. The most studied variants in this gene are the <italic>PvuII</italic> (C/T) and <italic>XbaI</italic> (G/A) polymorphisms in intron 1, 397 and 351&#x000a0;bp upstream of exon 2 respectively [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. These variants have been implicated in gene expression by influencing transcription [<xref ref-type="bibr" rid="CR10">10</xref>]. While some studies have found an increased risk for the A and T alleles of the <italic>XbaI</italic> and <italic>PvuII</italic> polymorphisms [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], others have found an increased risk only for the X (G) allele of <italic>XbaI</italic> [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In addition, other studies found no effect at all for either of these polymorphisms [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. These alleles were correlated with high bone mineral density and height in other studies, including one performed in our study population, [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], suggesting a stronger estrogenic effect in P(C) and X(G) allele carriers [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>The aim of our study was to evaluate the effect of these polymorphisms on breast cancer risk by performing an association analysis in a population based study of Caucasian postmenopausal women. Further, we performed meta-analyses of all available published data on these polymorphisms and the risk of breast cancer.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Study population and measurements</title><p>Our study population is part of the Rotterdam study [<xref ref-type="bibr" rid="CR16">16</xref>]. Inhabitants of the suburb of Ommoord aged 55 or older were invited to participate and 7983 agreed to do so (response rate 78.1%). Study participants signed an informed consent and the Medical Ethics Committee of the Erasmus Medical Center approved the study. Our study group was composed of 4,878 postmenopausal women. Information on risk factors such as age at entry, age at menarche, age at menopause, parity, body mass index (BMI), waist hip ratio (WHR) and hormone replacement therapy use (HRT) was retrieved at baseline through a questionnaire. BMI was calculated by dividing the weight in kilograms by the height (in meters) squared [<xref ref-type="bibr" rid="CR17">17</xref>].</p></sec><sec id="Sec4"><title>Case identification and validation</title><p>Three different databases were used for patient identification. First, cases diagnosed by general practitioners in the research area (Ommoord) were collected (International Classification of Primary Care (code X76)). Second, the Dutch National Registry of all hospital admissions (LMR) was consulted to detect all malignancy related hospital admissions for study participants. Finally, regional pathology databases were linked to the Rotterdam Study to identify patients. Subsequently, breast cancer cases were validated by a physician on the basis of medical records of the general practitioner, discharge letters and pathology reports. Only pathologically confirmed cases were considered in the analysis. The index date was defined as the earliest date found in the pathology report.</p></sec><sec id="Sec5"><title>Genotyping &#x00026; data analysis</title><p>Out of the 4,878 women participating in our study, 3,893 (80 %) were successfully genotyped for the <italic>PvuII</italic> and <italic>XbaI</italic> polymorphisms. The genotyping procedures have been described previously [<xref ref-type="bibr" rid="CR14">14</xref>]. Loss to follow up was assessed to verify it was independent of genotype. Categorical variables, such as parity and HRT, were compared between genotype groups using the chi-squared test. Continuous variables, (age at entry, age at menopause, BMI and WHR) were compared using the independent sample Mann&#x02013;Whitney test. We used logistic regression to study the risk of breast cancer by ESR1 genotype. This analysis was performed using SPSS version 11, since there is no clear risk allele from the literature, we took the TT (<italic>PvuII</italic>) and AA (<italic>XbaI</italic>) genotypes as reference because they have been associated to lower sensitivity to estrogen in our population [<xref ref-type="bibr" rid="CR14">14</xref>]. We also performed a trend test to evaluate if the number of risk alleles carried had an effect on disease risk. Hardy-Weinberg equilibrium (HWE) was assessed for both polymorphisms using Markov-Chain Monte-Carlo approximation of the exact test implemented in the GENEPOP package V 3.3 [<xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec6"><title>Meta-analysis</title><p>We searched PubMed until October 2006 for all case-control studies on the association of the <italic>PvuII</italic> and <italic>XbaI</italic> polymorphisms in the ESR1 gene and breast cancer. Our search strategy was based on the keyword &#x0201c;breast cancer&#x0201d; combined with &#x0201c;estrogen receptor&#x0201d; and &#x0201c;polymorphism&#x0201d;<italic>.</italic> To verify that all studies were retrieved, the reference lists of all publications were searched for additional studies. We excluded studies from our analyses if the genotype frequencies in the control population were out of Hardy-Weinberg or if their data had been previously used in another study. To quantify the strength of association, pooled odds ratios (ORs) and 95% confidence intervals (CI) were calculated using the random-effects model of the DerSimonian and Laird method [<xref ref-type="bibr" rid="CR19">19</xref>]. The degree of heterogeneity between the study results was tested by the inconsistency statistic (<italic>I</italic><sup>2</sup>). Funnel plots were used to evaluate publication bias [<xref ref-type="bibr" rid="CR20">20</xref>]. Data were analysed using Review Manager, version 4.2 (Cochrane Collaboration, Oxford, UK).</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>The total loss of follow-up for the genotyped participants was 8.4% and it was not dependent on ESR1 genotype (<italic>P</italic>&#x000a0;=&#x000a0;0.51). The genotype frequencies of both polymorphisms were in HWE proportions (<italic>X</italic><sup>2 </sup><italic>P</italic>&#x000a0;=&#x000a0;0.33 for <italic>PvuII</italic> and <italic>X</italic><sup>2</sup><italic>P</italic>&#x000a0;=&#x000a0;0.31 for <italic>XbaI</italic>). In Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> we show the baseline characteristics of our study population. We found that all cases (incident and prevalent) were significantly younger at entry than controls (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and also died earlier during follow-up (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), when using incident cases only we found the same significant differences (<italic>P</italic> for age at entry &#x0003c;0.0001, <italic>P</italic> for age at death &#x0003c;0.0001). We also found that cases had significantly fewer children than controls (<italic>P</italic>&#x000a0;=&#x000a0;0.04). We did not find any significant differences in these baseline characteristics between genotype groups (data not shown). <table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>General characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Cases</th><th align="left">Controls</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left">Total studied (%)</td><td align="left">190 (4.7%)</td><td align="left">3513 (95.3)</td><td align="left">3703</td></tr><tr><td align="left">Mean age of entry (SD)*</td><td align="left">67.80 (7.7)</td><td align="left">70.36 (9.6)</td><td align="left">70.24 (9.6)</td></tr><tr><td align="left">Mean age at death (SD)*</td><td align="left">77.30 (8.6)</td><td align="left">84.46 (8.7)</td><td align="left">84.12 (8.8)</td></tr><tr><td align="left">Mean age at menarche (SD)</td><td align="left">13.57 (1.7)</td><td align="left">13.68 (1.8)</td><td align="left">13.67 (1.8)</td></tr><tr><td align="left">Mean age at menopause (SD)*</td><td align="left">49.51 (4.8)</td><td align="left">52.19 (13.6)</td><td align="left">52.07 (13.3)</td></tr><tr><td align="left">Mean number of children (SD)*</td><td align="left">1.77 (1.6)</td><td align="left">2.12 (1.7)</td><td align="left">2.10 (1.7)</td></tr><tr><td align="left">Parity (SD) (&#x02265;1 child)*</td><td align="left">121 (71.6)</td><td align="left">2640 (79.4)</td><td align="left">2761 (79)</td></tr><tr><td align="left">Hormone replacement therapy(%)</td><td align="left">27 (21.1)</td><td align="left">504 (19.5)</td><td align="left">531 (19.6)</td></tr><tr><td align="left">Mean BMI (SD)</td><td align="left">27.10 (3.9)</td><td align="left">26.67 (4.1)</td><td align="left">26.69 (4.1)</td></tr><tr><td align="left">Mean WHR (SD)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td><td align="left">0.87 (.09)</td></tr></tbody></table><table-wrap-foot><p>*&#x000a0;<italic>P</italic>-value&#x000a0;&#x0003c;&#x000a0;0.05</p></table-wrap-foot></table-wrap></p><p>There were 38 women with previously diagnosed postmenopausal breast cancer who entered the study. During follow-up, 152 were additionally diagnosed. There were no significant differences in the number of cases between the <italic>PvuII</italic> (<italic>P</italic>&#x000a0;=&#x000a0;0.43 for overall cases) and <italic>XbaI</italic> genotypes (<italic>P</italic>&#x000a0;=&#x000a0;0.33 for overall cases).</p><p>We carried out a logistic regression analysis adjusting for age at entry, age at menopause, BMI, WHR and HRT for both polymorphisms separately (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Since the T and A alleles of these polymorphisms have been correlated to lower estrogenic effects, we used the TT and AA genotypes as our reference categories in the analyses. There were no significant differences in risk for breast cancer among carriers of the different genotypes of the <italic>PvuII</italic> or <italic>XbaI</italic> polymorphisms in the ESR1 gene. There was a non-significant tendency of the C allele of <italic>PvuII</italic> (<italic>P</italic>-for trend&#x000a0;=&#x000a0;0.22) and G allele of the <italic>XbaI</italic> (<italic>P</italic>-for trend 0.26) to be over represented in patients. <table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Odds ratios for breast cancer risk for <italic>PvuII</italic> and <italic>XbaI</italic> genotypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Overall</th><th align="left">Incident</th><th align="left">Prevalent</th></tr></thead><tbody><tr><td align="left" colspan="4"><italic>PvuII</italic></td></tr><tr><td align="left">TT</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr><tr><td align="left">TC</td><td char="." align="char">0.9 (0.6&#x02013;1.4)</td><td char="." align="char">1.0 (0.6&#x02013;1.6)</td><td char="." align="char">0.8 (0.3&#x02013;2.1)</td></tr><tr><td align="left">CC</td><td char="." align="char">1.4 (0.8&#x02013;2.2)</td><td char="." align="char">1.4 (0.8&#x02013;2.5)</td><td char="." align="char">1.2 (0.4&#x02013;3.3)</td></tr><tr><td align="left" colspan="4"><bold><italic>XbaI</italic></bold></td></tr><tr><td align="left">AA</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td><td char="." align="char">Ref</td></tr><tr><td align="left">GA</td><td char="." align="char">1.2 (0.8&#x02013;1.7)</td><td char="." align="char">1.3 (0.8&#x02013;2.0)</td><td char="." align="char">0.8 (0.4&#x02013;1.9)</td></tr><tr><td align="left">GG</td><td char="." align="char">1.3 (0.7&#x02013;2.2)</td><td char="." align="char">1.5 (0.8&#x02013;2.8)</td><td char="." align="char">0.5 (0.2&#x02013;2.4)</td></tr></tbody></table></table-wrap></p><p>To evaluate our data together with those in the literature we performed meta-analyses. We identified nine articles studying the relation between <italic>XbaI</italic> and <italic>PvuII</italic> polymorphisms and the risk of breast cancer [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. We excluded from our analyses one study [<xref ref-type="bibr" rid="CR11">11</xref>], since the data was used in another study [<xref ref-type="bibr" rid="CR4">4</xref>]. Furthermore, two studies were excluded since genotype frequencies of controls were out of HWE proportions [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Using the random effects model we did not find any difference in risk among <italic>XbaI</italic> and <italic>PvuII</italic> genotypes (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). High inter-study heterogeneity can render the interpretation of the results of a meta-analysis difficult and although we found high heterogeneity in the G/A versus GG comparison there was no significant heterogeneity in the other three comparisons. Additionally, the evaluation of the funnel plots did not suggest evidence for publication bias. <fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Meta-Analyses ESR1 <italic>XbaI</italic> polymorphism and breast cancer risk</p></caption><graphic position="anchor" xlink:href="10549_2007_9562_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Meta Analysis ESR1 <italic>PvuII</italic> polymorphism and breast cancer risk</p></caption><graphic position="anchor" xlink:href="10549_2007_9562_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec8" sec-type="discussion"><title>Discussion</title><p>We performed an association study to evaluate the relationship of two well-studied polymorphisms in the ESR1 gene and the risk of breast cancer in Caucasian postmenopausal women from the Rotterdam Study. Using logistic regression analysis, we found no evidence of effect, with only a non-significant increase in breast cancer risk for AA carriers of the <italic>XbaI</italic> polymorphism (overall OR&#x000a0;=&#x000a0;1.3, 95% CI&#x000a0;=&#x000a0;0.7&#x02013;2.2) and for TT carriers of the <italic>PvuII</italic> variant (overall OR&#x000a0;=&#x000a0;1.4, 95% CI&#x000a0;=&#x000a0;0.8&#x02013;2.2). Additionally we performed meta-analyses of published data to examine the effect of both polymorphisms. These meta-analyses also suggest there are no differences in risk among genotype groups of these two ESR1 variants.</p><p>The <italic>XbaI</italic> and <italic>PvuII</italic> polymorphisms are situated in intron 1 and their functionality has not yet been demonstrated. Moreover, it has been suggested their effects could be the result of high linkage disequilibrium with functional variants that affect sensitivity to estrogen [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>One of the limitations of our study is the limited number of breast cancer cases present in our population. Nevertheless, we have sufficient power (&#x003b2;&#x000a0;=&#x000a0;0.8) to detect effects of 1.6 or higher. We further conducted meta-analyses off all studies conducted to date. Our data suggests that these two polymorphisms do not play a role in the susceptibility of breast cancer in elderly Caucasian women.</p></sec></body><back><ack><title>Acknowledgements</title><p>A Arias Vasquez is supported by a grant from the Center of Medical Systems Biology, grant # 297&#x02013;2003. The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam.</p><p>These sponsors had no role in study design, data collection, data interpretation, or the writing of this report. A Arias V&#x000e1;squez contributed with the design of the study and also participated in the data analyses. CM van Duijn participated in the design and writing of the manuscript. F Rivadeneira, J Witteman, HAP Pols, BHCh Stricker, AG Uitterlinden and A Hofman aided in the data collection and the writing of this manuscript as well.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="other">Hulka BS, Moorman PG (2001) Breast cancer: hormones and other risk factors. Maturitas 38(1):103&#x02013;13; discussion 113&#x02013;116</citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lichtenstein</surname><given-names>P</given-names></name><name><surname>Holm</surname><given-names>NV</given-names></name><name><surname>Verkasalo</surname><given-names>PK</given-names></name><name><surname>Iliadou</surname><given-names>A</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Koskenvuo</surname><given-names>M</given-names></name></person-group><article-title>Environmental and heritable factors in the causation of cancer&#x02013;analyses of cohorts of twins from Sweden, Denmark, and Finland</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><issue>2</issue><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1056/NEJM200007133430201</pub-id></citation><citation citation-type="display-unstructured">Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et&#x000a0;al (2000) Environmental and heritable factors in the causation of cancer&#x02013;analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78&#x02013;85 <pub-id pub-id-type="pmid">10891514</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feigelson</surname><given-names>HS</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name></person-group><article-title>Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention</article-title><source>Breast Cancer Res</source><year>2000</year><volume>2</volume><issue>4</issue><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1186/bcr69</pub-id></citation><citation citation-type="display-unstructured">Feigelson HS, Henderson BE (2000) Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res 2(4):277&#x02013;282 <pub-id pub-id-type="pmid">11250721</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Nishio</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Park</surname><given-names>SK</given-names></name><name><surname>Kim</surname><given-names>SU</given-names></name></person-group><article-title>Estrogen receptor alpha gene polymorphisms and breast cancer risk</article-title><source>Breast Cancer Res Treat</source><year>2003</year><volume>80</volume><issue>1</issue><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1023/A:1024439202528</pub-id></citation><citation citation-type="display-unstructured">Shin A, Kang D, Nishio H, Lee MJ, Park SK, Kim SU et&#x000a0;al (2003) Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 80(1):127&#x02013;131 <pub-id pub-id-type="pmid">12889606</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Ahn</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name></person-group><article-title>Full sequencing analysis of estrogen receptor-alpha gene polymorphism and its association with breast cancer risk</article-title><source>Anticancer Res</source><year>2003</year><volume>23</volume><issue>6C</issue><fpage>4703</fpage><lpage>4707</lpage></citation><citation citation-type="display-unstructured">Han W, Kang D, Lee KM, Kim HJ, Ahn SJ, Kim SW et&#x000a0;al (2003) Full sequencing analysis of estrogen receptor-alpha gene polymorphism and its association with breast cancer risk. Anticancer Res 23(6C):4703&#x02013;4707 <pub-id pub-id-type="pmid">14981916</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gosden</surname><given-names>JR</given-names></name><name><surname>Middleton</surname><given-names>PG</given-names></name><name><surname>Rout</surname><given-names>D</given-names></name></person-group><article-title>Localization of the human oestrogen receptor gene to chromosome 6q24&#x02014;q27 by in situ hybridization</article-title><source>Cytogenet Cell Genet</source><year>1986</year><volume>43</volume><issue>3&#x02013;4</issue><fpage>218</fpage><lpage>220</lpage></citation><citation citation-type="display-unstructured">Gosden JR, Middleton PG, Rout D (1986) Localization of the human oestrogen receptor gene to chromosome 6q24&#x02014;q27 by in situ hybridization. Cytogenet Cell Genet 43(3&#x02013;4):218&#x02013;220 <pub-id pub-id-type="pmid">3802924</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ponglikitmongkol</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><article-title>Genomic organization of the human oestrogen receptor gene</article-title><source>Embo J</source><year>1988</year><volume>7</volume><issue>11</issue><fpage>3385</fpage><lpage>3388</lpage></citation><citation citation-type="display-unstructured">Ponglikitmongkol M, Green S, Chambon P (1988) Genomic organization of the human oestrogen receptor gene. Embo J 7(11):3385&#x02013;3388 <pub-id pub-id-type="pmid">3145193</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castagnoli</surname><given-names>A</given-names></name><name><surname>Maestri</surname><given-names>I</given-names></name><name><surname>Bernardi</surname><given-names>F</given-names></name><name><surname>Senno</surname><given-names>L</given-names></name></person-group><article-title>PvuII RFLP inside the human estrogen receptor gene</article-title><source>Nucleic Acids Res</source><year>1987</year><volume>15</volume><issue>2</issue><fpage>866</fpage><pub-id pub-id-type="doi">10.1093/nar/15.2.866</pub-id></citation><citation citation-type="display-unstructured">Castagnoli A, Maestri I, Bernardi F, Del Senno L (1987) PvuII RFLP inside the human estrogen receptor gene. Nucleic Acids Res 15(2):866 <pub-id pub-id-type="pmid">2881267</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>TI</given-names></name><name><surname>Heimdal</surname><given-names>KR</given-names></name><name><surname>Skrede</surname><given-names>M</given-names></name><name><surname>Tveit</surname><given-names>K</given-names></name><name><surname>Berg</surname><given-names>K</given-names></name><name><surname>Borresen</surname><given-names>AL</given-names></name></person-group><article-title>Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility</article-title><source>Hum Genet</source><year>1994</year><volume>94</volume><issue>6</issue><fpage>665</fpage><lpage>670</lpage></citation><citation citation-type="display-unstructured">Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL (1994) Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 94(6):665&#x02013;670 <pub-id pub-id-type="pmid">7989041</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>JR</given-names></name></person-group><article-title>Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai breast cancer study</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2003</year><volume>12</volume><issue>9</issue><fpage>853</fpage><lpage>859</lpage></citation><citation citation-type="display-unstructured">Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR et&#x000a0;al (2003) Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev 12(9):853&#x02013;859 <pub-id pub-id-type="pmid">14504194</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Ahn</surname><given-names>SJ</given-names></name><name><surname>Bae</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>SK</given-names></name></person-group><article-title>Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk</article-title><source>Cancer Lett</source><year>2002</year><volume>178</volume><issue>2</issue><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(01)00861-8</pub-id></citation><citation citation-type="display-unstructured">Kang HJ, Kim SW, Kim HJ, Ahn SJ, Bae JY, Park SK et&#x000a0;al (2002) Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk. Cancer Lett 178(2):175&#x02013;180 <pub-id pub-id-type="pmid">11867202</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modugno</surname><given-names>F</given-names></name><name><surname>Zmuda</surname><given-names>JM</given-names></name><name><surname>Potter</surname><given-names>D</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Ziv</surname><given-names>E</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name></person-group><article-title>Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women</article-title><source>Int J Cancer</source><year>2005</year><volume>116</volume><issue>6</issue><fpage>984</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1002/ijc.21105</pub-id></citation><citation citation-type="display-unstructured">Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR et&#x000a0;al(2005) Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women. Int J Cancer 116(6):984&#x02013;991 <pub-id pub-id-type="pmid">15856463</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yaich</surname><given-names>L</given-names></name><name><surname>Dupont</surname><given-names>WD</given-names></name><name><surname>Cavener</surname><given-names>DR</given-names></name><name><surname>Parl</surname><given-names>FF</given-names></name></person-group><article-title>Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood</article-title><source>Cancer Res</source><year>1992</year><volume>52</volume><issue>1</issue><fpage>77</fpage><lpage>83</lpage></citation><citation citation-type="display-unstructured">Yaich L, Dupont WD, Cavener DR, Parl FF (1992) Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 52(1):77&#x02013;83 <pub-id pub-id-type="pmid">1345763</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meurs</surname><given-names>JB</given-names></name><name><surname>Schuit</surname><given-names>SC</given-names></name><name><surname>Weel</surname><given-names>AE</given-names></name><name><surname>Klift</surname><given-names>M</given-names></name><name><surname>Bergink</surname><given-names>AP</given-names></name><name><surname>Arp</surname><given-names>PP</given-names></name></person-group><article-title>Association of 5&#x02032; estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><issue>14</issue><fpage>1745</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddg176</pub-id></citation><citation citation-type="display-unstructured">van Meurs JB, Schuit SC, Weel AE, van der Klift M, Bergink AP, Arp PP et&#x000a0;al (2003) Association of 5&#x02032; estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet 12(14):1745&#x02013;1754 <pub-id pub-id-type="pmid">12837697</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuit</surname><given-names>SC</given-names></name><name><surname>Meurs</surname><given-names>JB</given-names></name><name><surname>Bergink</surname><given-names>AP</given-names></name><name><surname>Klift</surname><given-names>M</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Leusink</surname><given-names>G</given-names></name></person-group><article-title>Height in pre- and postmenopausal women is influenced by estrogen receptor alpha gene polymorphisms</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><issue>1</issue><fpage>303</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1210/jc.2003-031095</pub-id></citation><citation citation-type="display-unstructured">Schuit SC, van Meurs JB, Bergink AP, van der Klift M, Fang Y, Leusink G et&#x000a0;al (2004) Height in pre- and postmenopausal women is influenced by estrogen receptor alpha gene polymorphisms. J Clin Endocrinol Metab 89(1):303&#x02013;309 <pub-id pub-id-type="pmid">14715865</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Jong</surname><given-names>PT</given-names></name><name><surname>Ouweland</surname><given-names>FA</given-names></name></person-group><article-title>Determinants of disease and disability in the elderly: the Rotterdam Elderly Study</article-title><source>Eur J Epidemiol</source><year>1991</year><volume>7</volume><issue>4</issue><fpage>403</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1007/BF00145007</pub-id></citation><citation citation-type="display-unstructured">Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA (1991) Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7(4):403&#x02013;422 <pub-id pub-id-type="pmid">1833235</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garrow</surname><given-names>J</given-names></name></person-group><article-title>Quetelet index as indicator of obesity</article-title><source>Lancet</source><year>1986</year><volume>1</volume><issue>8491</issue><fpage>1219</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(86)91207-9</pub-id></citation><citation citation-type="display-unstructured">Garrow J (1986) Quetelet index as indicator of obesity. Lancet 1(8491):1219 <pub-id pub-id-type="pmid">2871462</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>MRF</given-names></name></person-group><article-title>Genepop (version 1.2): population genetics software for exact tests and ecumenism</article-title><source>J Heredity</source><year>1986</year><volume>86</volume><fpage>248</fpage><lpage>249</lpage></citation><citation citation-type="display-unstructured">Raymond MRF (1986) Genepop (version 1.2): population genetics software for exact tests and ecumenism. J Heredity 86:248&#x02013;249 </citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group><article-title>Meta-analysis in clinical trials</article-title><source>Control Clin Trials</source><year>1986</year><volume>7</volume><issue>3</issue><fpage>177</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/0197-2456(86)90046-2</pub-id></citation><citation citation-type="display-unstructured">DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177&#x02013;188 <pub-id pub-id-type="pmid">3802833</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macaskill</surname><given-names>P</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name><name><surname>Irwig</surname><given-names>L</given-names></name></person-group><article-title>A comparison of methods to detect publication bias in meta-analysis</article-title><source>Stat Med</source><year>2001</year><volume>20</volume><issue>4</issue><fpage>641</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1002/sim.698</pub-id></citation><citation citation-type="display-unstructured">Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20(4):641&#x02013;654 <pub-id pub-id-type="pmid">11223905</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>DK</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>E</given-names></name></person-group><article-title>Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2006</year><volume>15</volume><issue>2</issue><fpage>342</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-05-0485</pub-id></citation><citation citation-type="display-unstructured">Shen Y, Li DK, Wu J, Zhang Z, Gao E (2006) Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 15(2):342&#x02013;347 <pub-id pub-id-type="pmid">16492926</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wedren</surname><given-names>S</given-names></name><name><surname>Lovmar</surname><given-names>L</given-names></name><name><surname>Humphreys</surname><given-names>K</given-names></name><name><surname>Magnusson</surname><given-names>C</given-names></name><name><surname>Melhus</surname><given-names>H</given-names></name><name><surname>Syvanen</surname><given-names>AC</given-names></name></person-group><article-title>Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study</article-title><source>Breast Cancer Res</source><year>2004</year><volume>6</volume><issue>4</issue><fpage>R437</fpage><lpage>R449</lpage><pub-id pub-id-type="doi">10.1186/bcr811</pub-id></citation><citation citation-type="display-unstructured">Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, et&#x000a0;al (2004) Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 6(4):R437&#x02013;R449 <pub-id pub-id-type="pmid">15217512</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comings</surname><given-names>DE</given-names></name><name><surname>Gade-Andavolu</surname><given-names>R</given-names></name><name><surname>Cone</surname><given-names>LA</given-names></name><name><surname>Muhleman</surname><given-names>D</given-names></name><name><surname>MacMurray</surname><given-names>JP</given-names></name></person-group><article-title>A multigene test for the risk of sporadic breast carcinoma</article-title><source>Cancer</source><year>2003</year><volume>97</volume><issue>9</issue><fpage>2160</fpage><lpage>2170</lpage><pub-id pub-id-type="doi">10.1002/cncr.11340</pub-id></citation><citation citation-type="display-unstructured">Comings DE, Gade-Andavolu R, Cone LA, Muhleman D, MacMurray JP (2003) A multigene test for the risk of sporadic breast carcinoma. Cancer 97(9):2160&#x02013;2170 <pub-id pub-id-type="pmid">12712467</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onland-Moret</surname><given-names>NC</given-names></name><name><surname>Gils</surname><given-names>CH</given-names></name><name><surname>Roest</surname><given-names>M</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Peeters</surname><given-names>PH</given-names></name></person-group><article-title>The estrogen receptor alpha gene and breast cancer risk (The Netherlands)</article-title><source>Cancer Causes Control</source><year>2005</year><volume>16</volume><issue>10</issue><fpage>1195</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1007/s10552-005-0307-5</pub-id></citation><citation citation-type="display-unstructured">Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control 16(10):1195&#x02013;1202 <pub-id pub-id-type="pmid">16215870</pub-id></citation></ref></ref-list></back></article> 